Revotar Biopharmaceuticals Announces the Appointment of Ludwig Felber as Chief Financial Officer and Member of the Executive Board and the Election of Prof Dr Wolfgang Hartwig as New Supervisory Board Member
6/3/2009 2:37:29 PM
More...
|
Revotar Biopharmaceuticals Starts Phase II Clinical Trial in Psoriasis with its Bimosiamose 5% Cream
2/2/2009 3:09:16 PM
More...
|
Revotar Biopharmaceuticals Reports Positive Preclinical Data From A 4-Month Dermal Toxicity Study
10/29/2008 11:49:45 AM
More...
|
Revotar Biopharmaceuticals Reports Positive Phase I Data In Psoriasis With Its Bimosiamose 5% Cream
10/13/2008 2:23:09 PM
More...
|
Revotar Biopharmaceuticals Closes 5.3 Million EUR Series A Financing Round
9/22/2008 7:38:23 AM
More...
|
Revotar Biopharmaceuticals Reports First Positive Clinical Results From Phase IIa Study in COPD
10/31/2007 8:14:37 AM
More...
|
Portfolio-Company, Revotar Biopharmaceuticals Concludes Start-Up Development Agreement With US Pharmaceuticals Manufacturer
8/22/2006 1:40:58 PM
More...
|
FDA Grants Encysive Pharmaceuticals (ENCY) Orphan Drug Designation For Thelin
10/19/2005 5:12:10 PM
More...
|
Encysive Pharmaceuticals (ENCY) Restructures Agreement With Revotar Biopharmaceuticals
10/19/2005 5:10:53 PM
More...
|
Revotar Biopharmaceuticals Granted Orphan Drug Designation By The European Medicines Agency For Bimosiamose Disodium To Treat Patients Suffering From Acute Lung Injury
10/19/2005 5:09:13 PM
More...
|
|